quinazolines has been researched along with Hair Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bangerter, M; Brudler, O; Heinrich, B; Reimer, G | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Bañuls, J; Belinchon, I; Blanes, M; Massuti, B; Pascual, JC | 1 |
| Bolotin, D; Chu, DH; Fuchs, E; Polak, L; Wang, X; Williams, T | 1 |
| Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E | 1 |
| Gerber, PA; Homey, B | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
3 review(s) available for quinazolines and Hair Diseases
| Article | Year |
|---|---|
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis | 2007 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
4 other study(ies) available for quinazolines and Hair Diseases
| Article | Year |
|---|---|
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Neoplasms; Quinazolines | 2008 |
Trichomegaly following treatment with gefitinib (ZD1839).
Topics: Antineoplastic Agents; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Hair Diseases; Humans; Middle Aged; Quinazolines | 2004 |
AP-2alpha: a regulator of EGF receptor signaling and proliferation in skin epidermis.
Topics: Animals; Animals, Newborn; Calcium; Caspase 3; Caspases; Cell Proliferation; Chromatin Immunoprecipitation; Chromones; Dermis; DNA; Embryo, Mammalian; Enzyme Inhibitors; Epidermal Cells; Epidermal Growth Factor; Epidermis; ErbB Receptors; Gene Expression; Gene Expression Regulation; Hair Diseases; Integrases; Keratinocytes; Keratins; Ki-67 Antigen; MAP Kinase Signaling System; Mice; Mice, Transgenic; Morpholines; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin; Skin Abnormalities; Tetradecanoylphorbol Acetate; Transcription Factor AP-2; Transforming Growth Factor alpha; Tyrphostins | 2006 |
Images in clinical medicine. Erlotinib-induced hair alterations.
Topics: Erlotinib Hydrochloride; Hair Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |